U.S. Markets close in 1 hr 18 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
33.100-0.260 (-0.779%)
As of 2:42PM EDT. Market open.
People also watch
Full screen
Previous Close33.360
Bid33.090 x 10200
Ask33.100 x 8400
Day's Range33.060 - 33.450
52 Week Range29.830 - 35.380
Avg. Volume19,421,421
Market Cap197.54B
PE Ratio (TTM)27.86
Earnings DateN/A
Dividend & Yield1.28 (3.84%)
Ex-Dividend Date2017-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters16 minutes ago

    FDA approves Pfizer's drug for rare blood cancer

    The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. A boxed warning is the agency's severest form of warning reserved to caution against the most serious side effects. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a disease that will affect about 5,970 people in the United States this year and kill about 1,440, according to the National Cancer Institute.

  • Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
    Zacks5 hours ago

    Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

    Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.

  • Market Realist7 hours ago

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.